Emergency Response System Improvements for Cardiac Arrest
Trial Summary
What is the purpose of this trial?
RACE-CARS is a real-world cluster-randomized trial designed to evaluate a multifaceted community and health systems intervention aimed to improve outcomes of out-of-hospital cardiac arrest. RACE-CARS will enroll 50 counties in North Carolina that are estimated to have a total of approximately 20,000 patients with cardiac arrest over a 4-year intervention period. County "clusters" will be randomized in a 1:1 ratio to intervention versus usual care. The trial duration is 7 years, which includes a 6-month start-up (including recruitment and randomization) period, a 12-month intervention training phase, a 4-year intervention period, a 12-month follow-up for to assess quality of life in survivors of OHCA, and a 6-month close-out and data analysis period.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications.
What data supports the effectiveness of the treatment Comprehensive community training of lay people in CPR and AED use, Optimized first responder performance including earlier use of AEDs, Rapid cardiac arrest recognition that triggers immediate priority EMS/first responder dispatch by 911 operators, Systematic bystander resuscitation instruction by 911 operators?
Research shows that rapid defibrillation with AEDs (devices that can restart the heart) significantly improves survival rates in cardiac arrest cases. Studies indicate that training laypeople and first responders, like police and firefighters, to use AEDs can lead to quicker defibrillation and better outcomes. Additionally, dispatcher assistance can help laypeople effectively use AEDs, potentially increasing survival rates.12345
Is the emergency response system improvement for cardiac arrest safe for humans?
Research on layperson use of automated external defibrillators (AEDs) in public access defibrillation programs shows no significant safety issues, even when used by minimally trained responders. These programs are generally considered safe and are supported by organizations like the American Heart Association.12467
How does the treatment for improving emergency response systems for cardiac arrest differ from other treatments?
This treatment is unique because it focuses on a comprehensive community approach, training laypeople in CPR and AED use, optimizing first responder performance, and ensuring rapid recognition and dispatch by 911 operators, which is not typically emphasized in standard treatments. It aims to improve survival rates by reducing response times and increasing the availability of life-saving interventions before professional medical help arrives.128910
Research Team
Christopher Granger, MD
Principal Investigator
Duke University
Eligibility Criteria
The RACE-CARS trial is for patients who experience non-traumatic out-of-hospital cardiac arrest (OHCA) and are pulseless when first responders arrive or become pulseless in their presence. It's not for cases where resuscitation isn't attempted due to severe injuries, signs of death, decomposition, or a valid DNR order.Inclusion Criteria
Exclusion Criteria
Timeline
Start-up
Recruitment and randomization of county clusters
Intervention Training
Training phase for community CPR/AED, 911 dispatch optimization, and first responder performance improvement
Intervention
Implementation of the intervention across 50 counties
Follow-up
Assessment of quality of life in survivors of out-of-hospital cardiac arrest
Close-out and Data Analysis
Final data collection and analysis period
Treatment Details
Interventions
- Comprehensive community training of lay people in CPR and AED use.
- Optimized first responder performance including earlier use of AEDs.
- Rapid cardiac arrest recognition that triggers immediate priority EMS/first responder dispatch by 911 operators
- Systematic bystander resuscitation instruction by 911 operators
Find a Clinic Near You
Who Is Running the Clinical Trial?
Duke University
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Collaborator